Patents by Inventor Quan HAN
Quan HAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11961846Abstract: The application discloses an array substrate and a mother-board for array substrates. The array substrate includes a display area and a non-display area on a periphery of the display area. The non-display area is provided with an interface area. The array substrate includes: multiple signal lines extending in the display area and leading to the non-display area; multiple pads located in the interface Area, and each of the multiple pads is connected to a corresponding one of the multiple signal lines; and a short-circuiting component located in the non-display area, wherein the short-circuiting component is connected with the multiple pads, the multiple signal lines connected with the pads are short-circuited, and the short-circuiting component includes a patterned first metal structure. The array substrate according to embodiments of the present application can avoid problems caused by static electricity, such as, electrostatic damage or product defects.Type: GrantFiled: June 25, 2021Date of Patent: April 16, 2024Assignee: KunShan Go Visionox Opto Electronics Co., LtdInventors: Quan Liu, Xu Qin, Weilong Li, Lu Zhang, Siming Hu, Zhenzhen Han
-
Patent number: 11958789Abstract: A method for determining a consistency coefficient of a power-law cement grout includes: determining a water-cement ratio of the power-law cement grout; according to engineering practice requirements, determining a time required to determine the consistency coefficient of the power-law cement grout; and obtaining the consistency coefficient of the power-law cement grout. The method is accurate and reliable, requires less calculation, etc.; and has very high practical value and popularization value in environmental protection and ecological restoration.Type: GrantFiled: December 12, 2023Date of Patent: April 16, 2024Assignee: KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Zhi-quan Yang, Jun-fan Xiong, Ying-yan Zhu, Yi Yang, Yong-shun Han, Muhammad Asif Khan, Jian-bin Xie, Tian-bing Xiang, Bi-hua Zhang, Han-hua Xu, Jie Zhang, Shen-zhang Liu, Qi-jun Jia, Cheng-yin Ye, Gang Li
-
Patent number: 11952357Abstract: The present disclosure relates to the field of epoxide resin, and more particularly to an epoxide with a low total chlorine content and no heavy metal residues, and a preparation method thereof. Disclosed is an epoxide prepared from raw materials including an unsaturated cycloaliphatic compound containing a double bond, hydrogen peroxide, an organic acid compound, a solvent and an alkaline salt; wherein a molar ratio of the organic acid compound to the unsaturated cycloaliphatic compound containing a double bond is (1-1.5):1. The obtained epoxides obtained in the present disclosure have a high purity, a high yield, a low solvent content, low chroma, and a low chlorine and metal ion content; the reaction system is simple, environmentally friendly, safe and controllable, and the production cost is low, which can meet the technical and economic requirements and are suitable for large-scale industrial production.Type: GrantFiled: September 17, 2020Date of Patent: April 9, 2024Assignee: JIANGSU TETRA NEW MATERIAL TECHNOLOGY CO., LTD.Inventors: Jianwei Han, Quan Jia, Yangjun Chang, Xiangming Cao
-
Publication number: 20240113809Abstract: The present application provides an instruction encoding-based data processing method and apparatus, and a device. N-path error correction encoding is performed on an instruction in information to be processed to obtain N encoded instructions, the encoded instructions and encoded meta channel programs obtained by the error correction encoding are used to perform redundant processing on data to be processed to obtain N pieces of response data, and then error correction decoding is performed on the N pieces of response data to obtain processing result information of the information to be processed. Because the N encoded instructions are heterogeneous and the encoded meta channel programs used in the N-path processing are heterogeneous, the randomness of the processing process can be improved, generalized disturbance in the data processing process can be corrected in combination with the error correction encoding and decoding methods, and thus the security of data processing is improved.Type: ApplicationFiled: June 7, 2021Publication date: April 4, 2024Inventors: Lei HE, Jiangxing WU, Quan REN, Zhen ZHANG, Weitao HAN, Fengyu ZHANG, Zheng YUAN, Yiwei GUO, Zhifeng FENG
-
Patent number: 11913409Abstract: The present disclosure relates to an afterburner structure with fuel injection nozzles. In the condition of a stable inlet flow, the present disclosure forms a sweeping oscillating jet with a certain frequency at the outlet under an alternate feedback action of a feedback channel and the fluid's Coanda effect, so that the spatial uniformity of the fuel injection is improved; Therefore, without increasing the structural complexity of current afterburner of the turbo-engine and the combustion chamber of the subsonic combustion ramjet, the atomization performance and the uniformity of the oil-gas mixture in the afterburner/combustion chamber of the ramjet can be greatly improved, the combustion efficiency and combustion instability of the engine can be improved and meanwhile the length of the afterburner and the combustion chamber of the subsonic combustion ramjet is shortened.Type: GrantFiled: February 23, 2023Date of Patent: February 27, 2024Assignee: AERO ENGINE ACADEMY OF CHINAInventors: Shiqi Wang, Quan Wen, Xiao Han
-
Patent number: 11679097Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a biguanide compound (e.g., metformin, metformin hydrochloride, buformin, and phenformin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes, for lipid-lowering and weight-loss, and the like.Type: GrantFiled: July 13, 2018Date of Patent: June 20, 2023Assignee: ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD.Inventors: Dong Li, Quan Han, Liu Hu, Lian Xue
-
Publication number: 20220313708Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a glucose cotransporter-2 inhibitor (SGLT-2) inhibitor (e.g., canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin and tofogliflozin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.Type: ApplicationFiled: July 30, 2020Publication date: October 6, 2022Inventors: Dong LI, Quan HAN, Liu HU, Lian XUE
-
Publication number: 20220296615Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a sulfonylurea compound (e.g., glibenclamide, gliclazide, glipizide, gliquidone and glimepiride). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.Type: ApplicationFiled: July 30, 2020Publication date: September 22, 2022Inventors: Dong LI, Quan HAN, Liu HU, Lian XUE
-
Publication number: 20220288046Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a thiazolidinedione compound (e.g., rosiglitazone, pioglitazone and the like). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like.Type: ApplicationFiled: July 30, 2020Publication date: September 15, 2022Inventors: Dong LI, Quan HAN, Liu HU, Lian XUE
-
Publication number: 20220125757Abstract: The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a biguanide compound (e.g., metformin, metformin hydrochloride, buformin, and phenformin). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes, for lipid-lowering and weight-loss, and the like.Type: ApplicationFiled: July 13, 2018Publication date: April 28, 2022Inventors: Dong LI, Quan HAN, Liu HU, Lian XUE
-
Patent number: 10407487Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: GrantFiled: September 25, 2017Date of Patent: September 10, 2019Assignee: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20180072791Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: September 25, 2017Publication date: March 15, 2018Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 9809638Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: GrantFiled: June 2, 2016Date of Patent: November 7, 2017Assignee: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 9447165Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: GrantFiled: March 11, 2014Date of Patent: September 20, 2016Assignee: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20160264644Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: June 2, 2016Publication date: September 15, 2016Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 9382309Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: GrantFiled: March 11, 2014Date of Patent: July 5, 2016Assignee: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20140194355Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: March 11, 2014Publication date: July 10, 2014Applicant: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 8753627Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.Type: GrantFiled: July 16, 2012Date of Patent: June 17, 2014Assignee: Amgen Inc.Inventors: Hui-Quan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 8716459Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: GrantFiled: April 5, 2011Date of Patent: May 6, 2014Assignee: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 8501678Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: GrantFiled: December 19, 2011Date of Patent: August 6, 2013Assignee: Atara Biotherapeutics, Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou, John Lu